{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:20:45Z","timestamp":1794961245713,"version":"4.9.1"},"reference-count":134,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.neurol.2022.09.003","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T21:24:58Z","timestamp":1668029098000},"page":"161-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Overview of the blood biomarkers in Alzheimer's disease: Promises and challenges"],"prefix":"10.1016","volume":"179","author":[{"given":"C.","family":"Delaby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hirtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2022.09.003_bib0680","first-page":"325","article-title":"Alzheimer's disease facts and figures. Alzheimer's &amp","author":"Alzheimer's Association","year":"2017","journal-title":"Dementia"},{"key":"10.1016\/j.neurol.2022.09.003_bib0685","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1756-6606-4-3","article-title":"APP processing in Alzheimer's disease","author":"Zhang","year":"2011","journal-title":"Mol Brain"},{"key":"10.1016\/j.neurol.2022.09.003_bib0690","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1471-4159.2011.07519.x","article-title":"Proteolytic processing of Alzheimer's \u03b2-amyloid precursor protein","author":"Zhang","year":"2012","journal-title":"J Neurochem"},{"key":"10.1016\/j.neurol.2022.09.003_bib0695","doi-asserted-by":"crossref","first-page":"103995","DOI":"10.1016\/j.archger.2019.103995","article-title":"Elevation of plasma soluble amyloid precursor protein beta in Alzheimer's disease","author":"Yun","year":"2020","journal-title":"Archives of Gerontology and Geriatrics"},{"key":"10.1016\/j.neurol.2022.09.003_bib0700","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1038\/tp.2013.11","article-title":"Soluble amyloid precursor protein \u03b2 as blood-based biomarker of Alzheimer's disease","author":"Perneczky","year":"2013","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.neurol.2022.09.003_bib0705","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer's disease","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.neurol.2022.09.003_bib0710","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","article-title":"Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria","author":"Dubois","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2022.09.003_bib0715","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2022.09.003_bib0720","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fnagi.2018.00138","article-title":"Relevance of A\u03b242\/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale","author":"Lehmann","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.neurol.2022.09.003_bib0725","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13195-022-00967-z","article-title":"The A\u03b21-42\/A\u03b21-40 ratio in CSF is more strongly associated to tau markers and clinical progression than A\u03b21-42 alone","author":"Delaby","year":"2022","journal-title":"Alz Res Therapy"},{"key":"10.1016\/j.neurol.2022.09.003_bib0730","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","article-title":"Advantages and disadvantages of the use of the CSF Amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer's Disease","volume":"11","author":"Hansson","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurol.2022.09.003_bib0735","doi-asserted-by":"crossref","first-page":"122","DOI":"10.12779\/dnd.2016.15.4.122","article-title":"The Correlation Study between Plasma A\u03b2 Proteins and Cerebrospinal Fluid Alzheimer's Disease Biomarkers","volume":"15","author":"Shin","year":"2016","journal-title":"Dement Neurocogn Disord"},{"key":"10.1016\/j.neurol.2022.09.003_bib0740","first-page":"53","article-title":"Biomarkers with Plasma Amyloid \u03b2 and Tau Protein Assayed by Immunomagnetic Reduction in Patients with Amnestic Mild Cognitive Impairment and Alzheimer's Disease","volume":"31","author":"Lee","year":"2022","journal-title":"Acta Neurol Taiwan"},{"key":"10.1016\/j.neurol.2022.09.003_bib0745","doi-asserted-by":"crossref","first-page":"e1580","DOI":"10.1212\/WNL.0000000000009240","article-title":"Total A\u03b2 42 \/A\u03b2 40 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis","volume":"94","author":"Doecke","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.09.003_bib0750","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13195-021-00911-7","article-title":"Performance of the plasma A\u03b242\/A\u03b240 ratio, measured with a novel HPLC-MS\/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort","volume":"13","author":"Jang","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurol.2022.09.003_bib0755","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13195-019-0549-1","article-title":"Plasma A\u03b242\/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study","volume":"11","author":"P\u00e9rez-Grijalba","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurol.2022.09.003_bib0760","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","article-title":"Head-to-Head Comparison of 8 Plasma Amyloid-\u03b2 42\/40 Assays in Alzheimer Disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2022.09.003_bib0765","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2021-326603","article-title":"Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias","author":"Alcolea","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2022.09.003_bib0770","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2022.09.003_bib0775","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13195-021-00873-w","article-title":"Plasma amyloid-\u03b2 oligomerization assay as a pre-screening test for amyloid status","volume":"13","author":"Babapour Mofrad","year":"2021","journal-title":"Alz Res Therapy"},{"key":"10.1016\/j.neurol.2022.09.003_bib0780","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3233\/JAD-200061","article-title":"Blood Amyloid-\u03b2 Oligomerization as a Biomarker of Alzheimer's Disease: A Blinded Validation Study","volume":"75","author":"Youn","year":"2020","journal-title":"JAD"},{"key":"10.1016\/j.neurol.2022.09.003_bib0785","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13195-017-0324-0","article-title":"Oligomeric forms of amyloid-\u03b2 protein in plasma as a potential blood-based biomarker for Alzheimer's disease","volume":"9","author":"Wang","year":"2017","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurol.2022.09.003_bib0790","article-title":"An ultra-sensitive immunoassay detects and quantifies soluble A\u03b2 oligomers in human plasma","author":"Liu","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2022.09.003_bib0795","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0165-0173(00)00019-9","article-title":"Tau protein isoforms, phosphorylation and role in neurodegenerative disorders","volume":"33","author":"Bu\u00e9e","year":"2000","journal-title":"Brain Res Brain Res Rev"},{"key":"10.1016\/j.neurol.2022.09.003_bib0800","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2022.09.003_bib0805","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0304-3940(00)01697-9","article-title":"Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke","volume":"297","author":"Hesse","year":"2001","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neurol.2022.09.003_bib0810","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/jamaneurol.2013.6455","article-title":"Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry","volume":"71","author":"Skillb\u00e4ck","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2022.09.003_bib0815","doi-asserted-by":"crossref","DOI":"10.1007\/s00702-021-02443-8","article-title":"Comparison of cerebrospinal fluid tau, ptau(181), synuclein, and 14-3-3 for the detection of Creutzfeldt-Jakob disease in clinical practice","author":"Fayolle","year":"2022","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.neurol.2022.09.003_bib0820","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","article-title":"Plasma tau in Alzheimer disease","volume":"87","author":"Mattsson","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.09.003_bib0825","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/alzrt163","article-title":"Plasma tau levels in Alzheimer's disease","volume":"5","author":"Zetterberg","year":"2013","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurol.2022.09.003_bib0830","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jamaneurol.2017.1359","article-title":"Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging","volume":"74","author":"Mielke","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2022.09.003_bib0835","first-page":"684","article-title":"Blood biomarkers for brain injury in concussed professional ice hockey players. JAMA Neurol","volume":"71","author":"Shahim","year":"2014"},{"key":"10.1016\/j.neurol.2022.09.003_bib0840","doi-asserted-by":"crossref","DOI":"10.1177\/0271678X221075967","article-title":"Hypoxemia increases blood-brain barrier permeability during extreme apnea in humans","author":"Bailey","year":"2022","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.neurol.2022.09.003_bib0845","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12885-019-5287-z","article-title":"The prognostic value of the\u00a0Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases","volume":"19","author":"Darlix","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.neurol.2022.09.003_bib0850","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1046\/j.1471-4159.1999.0720741.x","article-title":"Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins","volume":"72","author":"Zemlan","year":"1999","journal-title":"J Neurochem"},{"key":"10.1016\/j.neurol.2022.09.003_bib0855","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neurobiolaging.2007.05.009","article-title":"Pattern of Tau forms in CSF is altered in progressive supranuclear palsy","volume":"30","author":"Borroni","year":"2009","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/j.neurol.2022.09.003_bib0860","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.dadm.2015.06.004","article-title":"Late-onset behavioral variant of frontotemporal lobar degeneration\u00a0versus Alzheimer's disease: Interest of cerebrospinal fluid\u00a0biomarker\u00a0ratios","volume":"1","author":"Marelli","year":"2015","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.neurol.2022.09.003_bib0865","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13195-018-0361-3","article-title":"Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic","volume":"10","author":"Paterson","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurol.2022.09.003_bib0870","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jalz.2015.10.009","article-title":"Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia","volume":"12","author":"Llorens","year":"2016","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2022.09.003_bib0875","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia","volume":"26","author":"Janelidze","year":"2020","journal-title":"Nature Medicine"},{"key":"10.1016\/j.neurol.2022.09.003_bib0880","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","article-title":"Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography","volume":"14","author":"Mielke","year":"2018","journal-title":"Alzheimer's & Dementia: The Journal of the Alzheimer's Association"},{"key":"10.1016\/j.neurol.2022.09.003_bib0885","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00702-022-02474-9","article-title":"Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles","volume":"129","author":"Delaby","year":"2022","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1016\/j.neurol.2022.09.003_bib0890","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","article-title":"A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease","volume":"26","author":"Barth\u00e9lemy","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2022.09.003_bib0895","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3233\/JAD-150962","article-title":"Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies","volume":"51","author":"Barth\u00e9lemy","year":"2016","journal-title":"J Alzheimer's Dis"},{"key":"10.1016\/j.neurol.2022.09.003_bib0900","doi-asserted-by":"crossref","first-page":"e20200861","DOI":"10.1084\/jem.20200861","article-title":"Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease","volume":"217","author":"Barth\u00e9lemy","year":"2020","journal-title":"J Exp Med"},{"key":"10.1016\/j.neurol.2022.09.003_bib0905","first-page":"S123","article-title":"Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration","volume":"1","author":"Wang","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.neurol.2022.09.003_bib0910","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1042\/BST0380967","article-title":"From tau phosphorylation to tau aggregation: what about neuronal death?","volume":"38","author":"Bu\u00e9e","year":"2010","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.neurol.2022.09.003_bib0915","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/pmic.201400189","article-title":"Quantitative phosphoproteomics of Alzheimer's disease reveals cross-talk between kinases and small heat shock proteins","volume":"15","author":"Dammer","year":"2015","journal-title":"Proteomics"},{"key":"10.1016\/j.neurol.2022.09.003_bib0920","article-title":"Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease","author":"Janelidze","year":"2020","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.neurol.2022.09.003_bib0925","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13195-020-00596-4","article-title":"Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification","volume":"12","author":"Barth\u00e9lemy","year":"2020","journal-title":"Alzheimer's Res Ther"},{"key":"10.1016\/j.neurol.2022.09.003_bib0930","doi-asserted-by":"crossref","first-page":"e1681","DOI":"10.1212\/WNL.0000000000012727","article-title":"Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays","volume":"97","author":"Leuzy","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2022.09.003_bib0935","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology","author":"Ashton","year":"2021","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurol.2022.09.003_bib0940","article-title":"Association of cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders","author":"Olsson","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2022.09.003_bib0945","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-66090-x","article-title":"Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders","author":"Delaby","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/j.neurol.2022.09.003_bib0950","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/ene.14063","article-title":"Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis","volume":"27","author":"Thouvenot","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2022.09.003_bib0955","doi-asserted-by":"crossref","DOI":"10.1007\/s40520-022-02095-y","article-title":"Plasma neurofilament light levels correlate with white matter damage prior to Alzheimer's disease: results from ADNI","author":"Nabizadeh","year":"2022","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.neurol.2022.09.003_bib0960","doi-asserted-by":"crossref","first-page":"e75091","DOI":"10.1371\/journal.pone.0075091","article-title":"Increased neurofilament light chain blood levels in neurodegenerative neurological diseases","volume":"8","author":"Gaiottino","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.neurol.2022.09.003_bib0965","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","article-title":"Association of plasma neurofilament light with neurodegeneration in patients with alzheimer disease","volume":"74","author":"Mattsson","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2022.09.003_bib0970","article-title":"Diagnostic value of plasma neurofilament light: A multicentre validation study","author":"Ashton","year":"2020","journal-title":"In Review"},{"key":"10.1016\/j.neurol.2022.09.003_bib0975","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1001\/jamaneurol.2020.4986","article-title":"Longitudinal Associations of Blood Phosphorylated Tau181 and neurofilament light chain with neurodegeneration in alzheimer disease","volume":"78","author":"Moscoso","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2022.09.003_bib0980","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0304-3940(02)01257-0","article-title":"Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease","volume":"336","author":"Petzold","year":"2003","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.neurol.2022.09.003_bib0985","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1742-2094-7-6","article-title":"Serum levels of S100B and NSE proteins in Alzheimer's disease patients","author":"Chaves","year":"2010","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurol.2022.09.003_bib0990","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0197-4580(01)00293-7","article-title":"The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease","volume":"22","author":"Mrak","year":"2001","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neurol.2022.09.003_bib0995","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.resuscitation.2008.08.024","article-title":"The ischemic heart as an extracerebral source for S100B","volume":"80","author":"Mazzini","year":"2009","journal-title":"Resuscitation"},{"key":"10.1016\/j.neurol.2022.09.003_bib1000","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease","author":"Chatterjee","year":"2021","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.neurol.2022.09.003_bib1005","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13195-020-00682-7","article-title":"Combination of plasma amyloid beta(1-42\/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology","author":"Verberk","year":"2020","journal-title":"Alz Res Therapy"},{"key":"10.1016\/j.neurol.2022.09.003_bib1010","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jalz.2019.09.004","article-title":"Plasma biomarkers of astrocytic and neuronal dysfunction in early and late-onset Alzheimer's disease","author":"Elahi","year":"2020","journal-title":"Alzheimer's &amp; Dementia"},{"key":"10.1016\/j.neurol.2022.09.003_bib1015","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","article-title":"Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the alzheimer disease continuum","author":"Benedet","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2022.09.003_bib1020","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer's disease","author":"Pereira","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2022.09.003_bib1025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1373\/clinchem.2011.172676","article-title":"Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke","author":"Foerch","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.neurol.2022.09.003_bib1030","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer's disease","author":"Heneka","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2022.09.003_bib1035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/14728222.2020.1738391","article-title":"Alzheimer's disease: microglia targets and their modulation to promote amyloid phagocytosis and mitigate neuroinflammation","author":"Anwar","year":"2020","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.neurol.2022.09.003_bib1040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13024-018-0298-9","article-title":"New insights into the role of TREM2 in Alzheimer's disease","author":"Gratuze","year":"2018","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurol.2022.09.003_bib1045","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.cell.2015.01.049","article-title":"TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model","volume":"160","author":"Wang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.neurol.2022.09.003_bib1050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jneuroim.2018.03.003","article-title":"Soluble TREM2 and biomarkers of central and peripheral inflammation in neurodegenerative disease","volume":"319","author":"Bekris","year":"2018","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2022.09.003_bib1055","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/jnnp-2018-319148","article-title":"Inflammatory markers in Alzheimer's disease and mild cognitive impairment: a meta-analysis and systematic review of 170 studies","author":"Shen","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2022.09.003_bib1060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13024-020-00374-8","article-title":"Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study","author":"Ma","year":"2020","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurol.2022.09.003_bib1065","first-page":"627931","article-title":"The sTREM2 Concentrations in the Blood: A Marker of Neurodegeneration?","author":"Ferri","year":"2020","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.neurol.2022.09.003_bib1070","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/ene.13583","article-title":"Increased expression of TREM2 in peripheral cells from mild cognitive impairment patients who progress into Alzheimer's disease","author":"Casati","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2022.09.003_bib1075","doi-asserted-by":"crossref","first-page":"E3452","DOI":"10.3390\/jcm9113452","article-title":"Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid \u03b2-40, Amyloid \u03b2-42, Tau Protein, and YKL-40: A Review","author":"Wilczy\u0144ska","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.neurol.2022.09.003_bib1080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-017-0226-4","article-title":"YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias","author":"Llorens","year":"2017","journal-title":"Mol Neurodegeneration"},{"key":"10.1016\/j.neurol.2022.09.003_bib1085","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","article-title":"YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease","author":"Craig-Schapiro","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.neurol.2022.09.003_bib1090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000492536","article-title":"Association of the Polymorphisms and Plasma Level of CHI3L1 with Alzheimer's Disease in the Chinese Han Population: A Case-Control Study","author":"Dai","year":"2019","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.neurol.2022.09.003_bib1095","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2174\/1567205013666160222112444","article-title":"Peripheral immune signatures in alzheimer disease","author":"Goldeck","year":"2016","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.neurol.2022.09.003_bib1100","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2174\/1567205016666190321154618","article-title":"Systemic and CNS Inflammation Crosstalk: Implications for Alzheimer's Disease","author":"Paouri","year":"2019","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.neurol.2022.09.003_bib1105","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/nm1653","article-title":"Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins","volume":"13","author":"Ray","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2022.09.003_bib1110","doi-asserted-by":"crossref","first-page":"e34341","DOI":"10.1371\/journal.pone.0034341","article-title":"Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset","volume":"7","author":"Johnstone","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2022.09.003_bib1115","first-page":"181","article-title":"Central nervous system and peripheral inflammatory processes in alzheimer's disease: biomarker profiling approach","author":"Delaby","year":"2015","journal-title":"Front Neurol"},{"key":"10.1016\/j.neurol.2022.09.003_bib1120","doi-asserted-by":"crossref","first-page":"10283","DOI":"10.1038\/s41598-021-89749-5","article-title":"NFL strongly correlates with TNF-R1 in the plasma of AD patients, but not with cognitive decline","author":"Delaby","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.neurol.2022.09.003_bib1125","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000245156","article-title":"Peripheral cytokines and chemokines in Alzheimer's disease","author":"Lee","year":"2009","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1016\/j.neurol.2022.09.003_bib1130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.brainres.2010.09.073","article-title":"Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease","author":"Thorsell","year":"2010","journal-title":"Brain Res"},{"key":"10.1016\/j.neurol.2022.09.003_bib1135","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13195-015-0124-3","article-title":"Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls","author":"Kvartsberg","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurol.2022.09.003_bib1140","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13195-020-00748-6","article-title":"Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays","author":"\u00d6hrfelt","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurol.2022.09.003_bib1145","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jalz.2015.05.012","article-title":"C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease","author":"De Vos","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.neurol.2022.09.003_bib1150","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41398-020-0801-2","article-title":"Neurogranin as a cognitive biomarker in cerebrospinal fluid and blood exosomes for Alzheimer's disease and mild cognitive impairment","author":"Liu","year":"2020","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.neurol.2022.09.003_bib1155","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-019-0320-x","article-title":"\u03b1-synuclein in the pathophysiology of Alzheimer's disease","author":"Twohig","year":"2019","journal-title":"Molecular Neurodegeneration"},{"key":"10.1016\/j.neurol.2022.09.003_bib1160","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00401-003-0725-y","article-title":"Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study","author":"Jellinger","year":"2003","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.neurol.2022.09.003_bib1165","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.3233\/JAD-171013","article-title":"A Longitudinal Study of Total and Phosphorylated \u03b1-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment","author":"Wang","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.neurol.2022.09.003_bib1170","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/JAD-181152","article-title":"Cerebrospinal fluid and plasma biomarkers in neurodegenerative diseases","author":"Seino","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.neurol.2022.09.003_bib1175","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jpsychires.2020.06.006","article-title":"Indicators of rapid cognitive decline in amnestic mild cognitive impairment: The role of plasma biomarkers using magnetically labeled immunoassays","author":"Tsai","year":"2020","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.neurol.2022.09.003_bib1180","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/nrn1537","article-title":"Iron, brain ageing and neurodegenerative disorders","author":"Zecca","year":"2004","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.neurol.2022.09.003_bib1185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/2051-5960-1-55","article-title":"The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer's disease","author":"Raha","year":"2013","journal-title":"Acta Neuropathol Commun"},{"key":"10.1016\/j.neurol.2022.09.003_bib1190","doi-asserted-by":"crossref","first-page":"215","DOI":"10.14336\/AD.2016.0811","article-title":"Serum hepcidin levels iron dyshomeostasis and cognitive loss in Alzheimer's disease","author":"Sternberg","year":"2017","journal-title":"Aging Dis"},{"key":"10.1016\/j.neurol.2022.09.003_bib1195","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3233\/JAD-200162","article-title":"Serum hepcidin levels in cognitively normal older adults with high neocortical amyloid-\u03b2 Load","author":"Chatterjee","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.neurol.2022.09.003_bib1200","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jns.2019.06.008","article-title":"Clinical utility of serum hepcidin and iron profile measurements in Alzheimer's disease","author":"Kweon","year":"2019","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2022.09.003_bib1205","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2003-03-0672","article-title":"Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation","author":"Ganz","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.neurol.2022.09.003_bib1210","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41588-018-0311-9","article-title":"Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk","author":"Jansen","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.neurol.2022.09.003_bib1215","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1212\/NXG.0000000000000517","article-title":"Association of blood-based transcriptional risk scores with biomarkers for Alzheimer disease","author":"Park","year":"2020","journal-title":"Neurol Genet"},{"key":"10.1016\/j.neurol.2022.09.003_bib1220","doi-asserted-by":"crossref","DOI":"10.1016\/j.jagp.2022.02.003","article-title":"Blood mRNA Expression in Alzheimer's Disease and dementia with lewy bodies","author":"Donaghy","year":"2022","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.neurol.2022.09.003_bib1225","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/YPG.0000000000000303","article-title":"Evaluation of hsa-let-7d-5p, hsa-let-7g-5p and hsa-miR-15b-5p plasma levels in patients with Alzheimer's disease","author":"Poursaei","year":"2022","journal-title":"Psychiatr Genet"},{"key":"10.1016\/j.neurol.2022.09.003_bib1230","doi-asserted-by":"crossref","first-page":"e12251","DOI":"10.1002\/dad2.12251","article-title":"Plasma microRNA vary in association with the progression of Alzheimer's disease","author":"Gu\u00e9vremont","year":"2022","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.neurol.2022.09.003_bib1235","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3233\/JAD-2012-120637","article-title":"Validation of AclarusDxTM, a blood-based transcriptomic signature for the diagnosis of Alzheimer's disease","author":"Fehlbaum-Beurdeley","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.neurol.2022.09.003_bib1240","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2174\/1567205014666170505101426","article-title":"Lipid Biomarkers in Alzheimer's Disease","author":"Zarrouk","year":"2018","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.neurol.2022.09.003_bib1245","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-215400","article-title":"Markers of cerebrovascular injury? inflammation, and plasma lipids are associated with alzheimer's disease cerebrospinal fluid biomarkers in cognitively normal persons","author":"Jansson","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.neurol.2022.09.003_bib1250","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","article-title":"The role of apolipoprotein E in Alzheimer's disease","author":"Kim","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.neurol.2022.09.003_bib1255","doi-asserted-by":"crossref","first-page":"767","DOI":"10.14348\/molcells.2014.0248","article-title":"Apolipoprotein E in synaptic plasticity and Alzheimer's disease: potential cellular and molecular mechanisms","author":"Kim","year":"2014","journal-title":"Mol Cells"},{"key":"10.1016\/j.neurol.2022.09.003_bib1260","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.neuron.2008.04.010","article-title":"ApoE promotes the proteolytic degradation of Abeta","author":"Jiang","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.neurol.2022.09.003_bib1265","first-page":"671","article-title":"Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease","author":"Wahrle","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.neurol.2022.09.003_bib1270","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2014.05.007","article-title":"ATP-binding cassette transporter A1: from metabolism to neurodegeneration","author":"Koldamova","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurol.2022.09.003_bib1275","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1194\/jlr.R075796","article-title":"Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies","author":"Shinohara","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.neurol.2022.09.003_bib1280","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1385\/JMN:23:3:247","article-title":"In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology","author":"Holtzman","year":"2004","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.neurol.2022.09.003_bib1285","doi-asserted-by":"crossref","first-page":"104507","DOI":"10.1016\/j.jprot.2022.104507","article-title":"Isotopic N, N-dimethyl leucine tags for absolute quantification of clusterin and apolipoprotein E in Alzheimer's disease","volume":"257","author":"Liu","year":"2022","journal-title":"J Proteomics"},{"key":"10.1016\/j.neurol.2022.09.003_bib1290","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/cells11010029","article-title":"Levels of angiotensin-converting enzyme and apolipoproteins are associated with alzheimer's disease and cardiovascular diseases","author":"Xu","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.neurol.2022.09.003_bib1295","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/alzrt257","article-title":"The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease","author":"Jochemsen","year":"2014","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.neurol.2022.09.003_bib1300","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1007\/s11033-021-06968-9","article-title":"Therapeutic potential of neurotrophic factors in Alzheimer's Disease","author":"Nasrolahi","year":"2022","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.neurol.2022.09.003_bib1305","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamaneurol.2013.4781","article-title":"Serum brain-derived neurotrophic factor and the risk for dementia: the Framingham Heart Study","author":"Weinstein","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2022.09.003_bib1310","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00441-020-03287-6","article-title":"GDNF synthesis, signaling, and retrograde transport in motor neurons","author":"Cintr\u00f3n-Col\u00f3n","year":"2020","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.neurol.2022.09.003_bib1315","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1007\/s10072-020-04909-1","article-title":"Do serum GDNF levels correlate with severity of Alzheimer's disease?","author":"Sharif","year":"2021","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurol.2022.09.003_bib1320","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1468-1331.2010.03273.x","article-title":"Brain-specific fatty acid-binding protein is elevated in serum of patients with dementia-related diseases","author":"Teunissen","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2022.09.003_bib1325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yfrne.2017.10.002","article-title":"Adiponectin and sporadic Alzheimer's disease: Clinical and molecular links","author":"Letra","year":"2019","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.neurol.2022.09.003_bib1330","first-page":"4981814","article-title":"Metabolism: a novel shared link between diabetes Mellitus and Alzheimer's Disease","author":"Sun","year":"2020","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.neurol.2022.09.003_bib1335","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/j.neurobiolaging.2014.03.006","article-title":"18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons","volume":"35","author":"Knopman","year":"2014","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neurol.2022.09.003_bib1340","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3233\/JAD-215153","article-title":"Diabetes Mellitus, Elevated Hemoglobin A1c, and Glycated Albumin Are Associated with the Presence of All-Cause Dementia and Alzheimer's Disease: The JPSC-AD Study","author":"Noguchi-Shinohara","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.neurol.2022.09.003_bib0675","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1038\/s41467-021-23746-0","article-title":"Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations","author":"Cullen","year":"2021","journal-title":"Nat Commun"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722007925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722007925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:45:54Z","timestamp":1758519954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378722007925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":134,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0035378722007925"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2022.09.003","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overview of the blood biomarkers in Alzheimer's disease: Promises and challenges","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2022.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}